Security
Silexion Therapeutics Corp Ordinary Shares · SLXN
SLXNNASDAQCommon stockCurrentCIK 2022416Updated Oct 29, 2026
Name history
Biomotion Sciences · through Aug 15, 2024
SLXN price & chart
Loading TradingView…
NASDAQ:SLXN on TradingView ↗About the company
We are a clinical-stage biotechnology company developing, through our subsidiaries, RNA interference (RNAi) therapies for cancers driven by mutations in the Kirsten rat sarcoma viral oncogene homolog (“KRAS”). Our approach targets a significant unmet medical need, as treatment innovation for KRAS-driven cancers has historically lagged despite KRAS being one of the most common oncogenic drivers across solid tumors. In pancreatic cancer, for example, approximately 92% of patients have this mutated oncogene. While multiple pharmaceutical companies are pursuing strategies to inhibit KRAS and thereby limit its downstream signaling, our approach is differentiated by targeting the root cause of oncogenic signaling; our lead product candidate, SIL204, is a second-generation siRNA therapy that is engineered to suppress the KRAS oncogene itself, preventing the production of the oncogenic protein. We utilize an integrated treatment approach that combines administering SIL204 both directly into the tumor and systemically via subcutaneous injection, in combination with standard-of-care chemotherapy. In a previous Phase 2 clinical trial with our first-generation siRNA, the combination of si…
In the news
Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences ↗
Recent filings
S-3 filing
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security Holders
Items 5.03, 5.07, 9.01
DEFA14A filing
DEF 14A filing
Regulation FD Disclosure
Items 7.01, 9.01
Show 5 more recent filings
424B3 filing
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Other Events
Items 1.01, 3.02, 8.01, 9.01
SCHEDULE 13D/A - filed by Moringa Sponsor, LP regarding Silexion Therapeutics Corp
Regulation FD Disclosure
Items 7.01, 9.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| AssetsUSD | 11,614,000Source | 3,087,000Source | 4,246,000Source | 5,797,000Source | 2,315,000Source | 4,602,000Source | 8,308,000Source | 3,585,000Source | 7,215,000Source | 2,863,000Source | 5,256,000Source |
| Property, Plant and Equipment, NetUSD | 26,000Source | 35,000Source | 20,000Source | 30,000Source | 40,000Source | 23,000Source | 32,000Source | — | 25,000Source | 30,000Source | 49,000Source |
| Current assets: | |||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 9,243,000Source | 1,973,000Source | 2,229,000Source | 3,466,000Source | 1,697,000Source | 2,413,000Source | 6,152,000Source | — | 5,991,000Source | 1,187,000Source | 4,595,000Source |
| Assets, CurrentUSD | 11,055,000Source | 3,047,000Source | 3,741,000Source | 5,237,000Source | 2,315,000Source | 4,065,000Source | 7,722,000Source | — | 6,637,000Source | 2,250,000Source | 4,979,000Source |
| Operating Lease, Right-of-Use AssetUSD | 442,000Source | 0Source | 348,000Source | 472,000Source | 140,000Source | 380,000Source | 502,000Source | — | 412,000Source | 530,000Source | 198,000Source |
| LIABILITIES AND EQUITY | |||||||||||
| LiabilitiesUSD | 4,637,000Source | 7,666,000Source | 4,202,000Source | 5,677,000Source | 2,372,000Source | 4,311,000Source | 5,722,000Source | — | 4,612,000Source | 6,852,000Source | 2,255,000Source |
| Stockholders’ equity: | |||||||||||
| Common Stock, Value, IssuedUSD | 42,000Source | 1,000Source | 160,000Source | 8,000Source | 1,000Source | 46,000Source | 8,000Source | — | 42,000Source | 2,000Source | — |
| Additional Paid in CapitalUSD | 57,689,000Source | 37,003,000Source | 61,334,000Source | 47,604,000Source | 11,398,000Source | 58,144,000Source | 47,567,000Source | — | 57,727,000Source | 39,263,000Source | 11,335,000Source |
| Retained Earnings (Accumulated Deficit)USD | -50,754,000Source | -41,583,000Source | -61,450,000Source | -47,492,000Source | -29,656,000Source | -57,899,000Source | -44,989,000Source | — | -55,166,000Source | -43,254,000Source | -26,811,000Source |
| Stockholders' Equity Attributable to ParentUSD | 6,977,000Source | -4,579,000Source | 44,000Source | 120,000Source | -18,257,000Source | 291,000Source | 2,586,000Source | — | 2,603,000Source | -3,989,000Source | -15,476,000Source |
| Liabilities and EquityUSD | 11,614,000Source | 3,087,000Source | 4,246,000Source | 5,797,000Source | 2,525,000Source | 4,602,000Source | 8,308,000Source | — | 7,215,000Source | 2,863,000Source | 5,256,000Source |
| Current liabilities: | |||||||||||
| Liabilities, CurrentUSD | 2,786,000Source | 3,583,000Source | 3,976,000Source | 2,150,000Source | 2,364,000Source | 4,060,000Source | 2,395,000Source | — | 2,758,000Source | 3,523,000Source | 2,196,000Source |
| Operating Lease, Liability, CurrentUSD | 174,000Source | 0Source | 199,000Source | 171,000Source | 108,000Source | 185,000Source | 155,000Source | — | 182,000Source | 158,000Source | 112,000Source |
| Accounts Payable, CurrentUSD | 946,000Source | 799,000Source | — | 692,000Source | 281,000Source | — | 722,000Source | — | 787,000Source | 929,000Source | 319,000Source |
| Operating Lease, Liability, NoncurrentUSD | 311,000Source | 0Source | 226,000Source | 337,000Source | 8,000Source | 251,000Source | 334,000Source | — | 286,000Source | 368,000Source | 59,000Source |
| Accrued Liabilities, Current | — | — | —Source | — | — | —Source | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -11,860,000Source | — | — | — | -1,735,000Source | -11,912,000Source | -16,519,000Source | -5,108,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 38,000Source | 5,798,000Source | 197,000Source | 37,000Source | 345,000Source | 21,000Source | 134,000Source | 5,862,000Source | 130,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | -2,843,000Source | -2,653,000Source | -2,925,000Source | -2,507,000Source | -3,646,000Source | -2,453,000Source | -10,819,000Source | -8,396,000Source | -4,529,000Source |
| Cash flows from investing activities: | |||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | 0Source | -16,000Source | -1,000Source | -1,000Source | 0Source | -6,000Source | -14,000Source | -22,000Source | 573,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | 0Source | 16,000Source | 0Source | 1,000Source | 0Source | 6,000Source | 9,000Source | 22,000Source | 12,000Source |
| Cash flows from financing activities: | |||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | 8,624,000Source | 2,920,000Source | 2,740,000Source | -195,000Source | 83,000Source | 7,432,000Source | 15,640,000Source | 5,104,000Source | 522,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 9,324,000Source | 2,023,000Source | 2,320,000Source | 3,544,000Source | 2,498,000Source | 6,233,000Source | 6,075,000Source | 1,270,000Source | 4,645,000Source |
| Supplemental disclosure of cash flow information: | |||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 13,000Source | 13,000Source | 27,000Source | 0Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | -1,000Source | 25,000Source | 8,000Source | 14,000Source | -14,000Source | -10,000Source | -2,000Source | -61,000Source | -230,000Source |
| Additional Financial Items | |||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 38,000Source | 5,798,000Source | 197,000Source | 37,000Source | 345,000Source | 21,000Source | 134,000Source | 5,862,000Source | 130,000Source |
| DepreciationUSD | — | — | 4,000Source | 22,000Source | 3,000Source | 3,000Source | 2,000Source | 4,000Source | 14,000Source | 25,000Source | 45,000Source |
| Financing Interest ExpenseUSD | — | — | 9,000Source | 3,822,000Source | — | 260,000Source | 16,000Source | 76,000Source | 419,000Source | 3,939,000Source | 548,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 32,000Source | 48,000Source | 40,000Source | 61,000Source | 27,000Source | -6,000Source | 127,000Source | 247,000Source | 453,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | 0Source | — | — | — | — | 0Source | -16,000Source | 1,000Source |
| Gain (Loss) on Termination of LeaseUSD | — | — | 0Source | -68,000Source | — | — | — | — | 0Source | -68,000Source | 0Source |
| General and Administrative ExpenseUSD | — | — | 1,135,000Source | 4,819,000Source | 1,468,000Source | 1,266,000Source | 1,379,000Source | 1,060,000Source | 4,492,000Source | 6,756,000Source | 973,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 2,000Source | — | 3,000Source | — | — | 3,000Source | 10,000Source | 32,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,262,000Source | -11,860,000Source | -3,551,000Source | -2,503,000Source | -2,733,000Source | -1,735,000Source | -11,912,000Source | -16,519,000Source | -5,108,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | 0Source | 9,000Source | — | 0Source | — | 0Source | 0Source | 76,000Source | 166,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | 3,262,000Source | 11,851,000Source | — | 2,503,000Source | — | 1,735,000Source | 11,912,000Source | 16,443,000Source | 4,942,000Source |
| Nonoperating Income (Expense)USD | — | — | -30,000Source | 3,822,000Source | -129,000Source | 216,000Source | -16,000Source | 85,000Source | 277,000Source | 3,938,000Source | 395,000Source |
| Operating ExpensesUSD | — | — | 3,292,000Source | 8,036,000Source | 3,680,000Source | 2,284,000Source | 2,749,000Source | 1,650,000Source | 11,632,000Source | 12,571,000Source | 4,681,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | 170,000Source | 144,000Source | 131,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 4,000Source | 3,000Source | -115,000Source | 260,000Source | 4,000Source | 3,000Source | 13,000Source | 7,000Source | 6,000Source |
| Payments for Repurchase of WarrantsUSD | — | — | 232,000Source | 0Source | 125,000Source | 100,000Source | 0Source | 362,000Source | 740,000Source | — | — |
| Proceeds from Noncontrolling InterestsUSD | — | — | 0Source | 3,344,000Source | — | — | — | — | 0Source | 3,344,000Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | 620,000Source | — | 0Source | — | 0Source | 0Source | 3,054,000Source | 0Source |
| Proceeds from Issuance of Common Stock | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -3,292,000Source | -8,036,000Source | -3,680,000Source | -2,284,000Source | -2,749,000Source | -1,650,000Source | -11,632,000Source | -12,571,000Source | -4,681,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 4,000Source | 3,000Source | -115,000Source | 260,000Source | 4,000Source | 3,000Source | 13,000Source | 7,000Source | 6,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -3,262,000Source | -11,858,000Source | -3,551,000Source | -2,500,000Source | -2,733,000Source | -1,735,000Source | -11,909,000Source | -16,509,000Source | -5,076,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 2,000Source | — | 3,000Source | — | — | 3,000Source | 10,000Source | 32,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | 0Source | 9,000Source | — | 0Source | — | 0Source | 0Source | 76,000Source | 166,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,262,000Source | -11,860,000Source | -3,551,000Source | -2,503,000Source | -2,733,000Source | -1,735,000Source | -11,912,000Source | -16,519,000Source | -5,108,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 2.88Source | 274.25Source | 5.17Source | 43.19Source | 0.85Source | 3.84Source | 8.96Source | 26.36Source | 44.23Source |
| Earnings Per Share, DilutedUSD per share | — | — | 2.88Source | 274.25Source | 5.17Source | 43.19Source | 0.85Source | 3.84Source | 8.96Source | 26.36Source | 44.23Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 1,132,658Source | 43,213Source | 687,353Source | 57,952Source | 3,230,378Source | 451,990Source | 1,329,515Source | 623,846Source | 111,726Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 1,132,658Source | 43,213Source | 687,353Source | 57,952Source | 3,230,378Source | 451,990Source | 1,329,515Source | 623,846Source | 111,726Source |
| Additional Financial Items | |||||||||||
| Financing Interest ExpenseUSD | — | — | 9,000Source | 3,822,000Source | — | 260,000Source | 16,000Source | 76,000Source | 419,000Source | 3,939,000Source | 548,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 32,000Source | 48,000Source | 40,000Source | 61,000Source | 27,000Source | -6,000Source | 127,000Source | 247,000Source | 453,000Source |
| General and Administrative ExpenseUSD | — | — | 1,135,000Source | 4,819,000Source | 1,468,000Source | 1,266,000Source | 1,379,000Source | 1,060,000Source | 4,492,000Source | 6,756,000Source | 973,000Source |
| InterestExpenseOperatingUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 11,000Source | 13,000Source | -27,000Source | 0Source |
| Interest Income, OtherUSD | — | — | 40,000Source | 0Source | 14,000Source | 44,000Source | 32,000Source | 2,000Source | 155,000Source | 28,000Source | 153,000Source |
| Interest Revenue (Expense), NetUSD | — | — | -39,000Source | 0Source | -14,000Source | -43,000Source | -32,000Source | 9,000Source | -142,000Source | -1,000Source | -153,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | 3,262,000Source | 11,851,000Source | — | 2,503,000Source | — | 1,735,000Source | 11,912,000Source | 16,443,000Source | 4,942,000Source |
| Nonoperating Income (Expense)USD | — | — | -30,000Source | 3,822,000Source | -129,000Source | 216,000Source | -16,000Source | 85,000Source | 277,000Source | 3,938,000Source | 395,000Source |
| Operating ExpensesUSD | — | — | 3,292,000Source | 8,036,000Source | 3,680,000Source | 2,284,000Source | 2,749,000Source | 1,650,000Source | 11,632,000Source | 12,571,000Source | 4,681,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | 170,000Source | 144,000Source | 131,000Source |
| Research and Development ExpenseUSD | — | — | 2,157,000Source | 3,217,000Source | 2,212,000Source | 1,018,000Source | 1,370,000Source | 590,000Source | 7,140,000Source | 5,815,000Source | 3,708,000Source |
Offerings
Registration 333-299675
Registration 333-298137
- Gross proceeds
- 2499822.9
- Net proceeds
- 2324822.57
- Deal price
- 0.65
- Shares
- 3845881
- Offering price
- $0.65
Underwriters: H.C. Wainwright & Co. LLC
Registration 333-296739
Registration 333-290074
- Gross proceeds
- 5999989.0
- Net proceeds
- 5579989.0
- Deal price
- 4.0
- Shares
- 1499997
- Offering price
- $4.00
Registration 333-289860
Registration 333-284873
Registration 333-282932
- Gross proceeds
- 4999843.0
- Net proceeds
- 4649843.0
- Deal price
- 1.35
- Shares
- 3703587
- Offering price
- $1.35
Filing attachments
ea030225001ex99-1.htm · SCHEDULE 13G · 2026-08-18
Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the inf…
Read attachment ↗ex107.htm · S-3 · 2026-06-12
Calculation of Filing Fee Tables S-3 Silexion Therapeutics Corp ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit …
Read attachment ↗ex107.htm · S-8 · 2026-02-19
Calculation of Filing Fee Tables S-8 Silexion Therapeutics Corp ──────────────────────────────────── Table 1: Newly Registered Securities ──────────────────────────────────────── Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee ───────────────…
Read attachment ↗ex107.htm · S-1 · 2025-09-05
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-1 Silexion Therapeutics Corp Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Amount Registered Proposed Maximum Offering Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee …
Read attachment ↗ex107.htm · S-1 · 2025-08-26
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-1 Silexion Therapeutics Corp Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Amount Registered Proposed Maximum Offering Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee …
Read attachment ↗